Figure 5

Effect of Treg depletion, via anti-mouse CD25 Ab or P60 treatment, on the anti-arthritic activity of PLA2 in DBA/1 mice with CIA. Fifty days after the first immunization injection, mice were analyzed based on body weight (A), the squeaking score (B), change (Δ) in paw volume (C), and the arthritis index (D). Clinical evaluations of mouse limbs were performed on day 50. NOR: untreated naïve group (n = 6); CIA: CIA group (n = 6); CIA_PLA2: 0.5 mg/kg bvPLA2-treated arthritis group (n = 6); anti-CD25 Ab: 0.5 mg/kg bvPLA2- and 0.25 mg/kg rat anti-mouse CD25 Ab-treated arthritis group (n = 6); P60: 0.5 mg/kg bvPLA2- and 10 μg/kg P60-treated arthritis group (n = 6); NOR Ab: 0.5 mg/kg bvPLA2- and 0.25 mg/kg normal rat Ab-treated arthritis group (n = 6); SCRAMB: 0.5 mg/kg PLA2- and 10 μg/kg scrambled P60-treated arthritis group (n = 6). One-way ANOVA followed by Newman–Keuls post hoc test was used for comparisons of arthritic behaviors above among the groups. For comparisons between Anti-CD25 Ab and NOR Ab groups, and P60 and SCRAMB groups, paired Student’s t-test were performed. In all analyses, statistical differences were considered significant at p < 0.05. ^###p < 0.001 vs. the NOR group, ^$$$p < 0.001 versus the CIA group, and *p < 0.05, **p < 0.01, ***p < 0.001 versus the CIA_PLA2 group. ^$$p < 0.01 (paired Student´s t-test within between Anti-CD25 Ab and NOR Ab groups), and ^&&&p < 0.001 (paired Student´s t-test within between P60 and SCRAMB groups).